But maybe he wasn't allowed to wait.... material info...???
He could have taken the 370K he paid for Fed/state tax for exercising and used that to exercise shares now... The company would have gotten the 370K instead of the Gov't.... just saying
While no standardized surgical approach to all patients with locally recurrent melanoma has been established, treatment guidelines have been developed based on clinical trials in patients selected by the extent and specific anatomic site of disease recurrence. The realization that local recurrence is not simply the result of inadequate surgical excision but is in fact an outward manifestation of the biological aggressiveness of the primary melanoma has lead to a more rational approach to the treatment of these patients.
Complete surgical resection with primary wound closure is the most straightforward means of treating single recurrent lesions. Patients with multiple subcutaneous metastases grouped within a single site can similarly be treated with wide local excision with skin grafting or flap closure as necessary for wound coverage. While wide resection margins are not as well defined in the resection of locally recurrent disease as they are in the treatment of primary cutaneous melanoma, recurrent lesions should be resected with a margin of normal tissue.
Unfortunately, despite complete surgical resection of multiple cutaneous metastases, further local and regional recurrence may occur in up to 67% of patients with locally recurrent malignant melanoma and is strongly associated with subsequent disease progression. As many as 70–82% of such patients ultimately succumb to distant metastases. Although systemic chemotherapy in the adjuvant setting is rarely effective, systemic immunotherapy, in the form of Interferon alpha-2b (Intron A) or a variety of experimental melanoma vaccines, may have a role in the treatment of patients subsequent to complete surgical resection of locally recurrent melanoma. The effectiveness of such modes of immunotherapy in improving survival in these patients, remains unproven.
Stage 1 and 2 is small???? What % of melanoma patients have lesions? Weber said it might be perfect in combo... So that takes care of stage 4. Argwala proposed that a use could be before surgery for melanoma and after.....
Wachter has invested all of his take home pay in the last 7 years about 3.6M dollars and used it to buy PVT placement stock and exercise all of his options. Culpepper has invested about 1M sollars over the last 7 years back into the company through PVT placement and exercise.
So should I listen to NTTG or the experts? Should I just discount that Wachter has invested all his take home pay back into the company?
Once PV-10 has been FDA-approved, I expect that caring oncologists will increasingly inject all melanoma with PV-10, in order to stimulate immunity, even if surgical resection of the tumors is planned. I expect that the eventual acquirer of Provectus will one day run a trial comparing Stage 1 and 2 melanoma patients' disease progression (or lack of it) comparing those who only had surgery with a group of patients who had PV-10 injections 2 weeks before surgery.
Culpepper activity....He had more activity before 2010 about 1M Invested not including stock Grants.
06/27/2014 Exercise of Stock Options Direct $125,000 100,000 1.25-1.25 1,233,330
02/26/2014 Exercise of Stock Options D / I $208,586 189,624 1.10-1.10 1,133,330
12/03/2012 Purchase Direct $100,000 133,333 0.75-0.75 943,708
11/16/2012 Purchase Direct $0 133,333 0.00-0.00 810,375
05/03/2011 Exercise of Stock Options Direct $100,000 133,333 0.75-0.75 677,042
12/29/2010 Exercise of Stock Options Direct $100,000 133,333 0.75-0.75 543,709
Conspiracy I see... Too bad PVCT's insiders left 100,000,000 on the table not one share sold.... A matter of fact if you do you homework and pull up the Insider transactions you will see that Culpepper has invested about 1M of his own money and Wachter about 3.6M when you include the Fed/state tax he had to pay on the last 640,000 share exercise. The other guy about 500K invested through exercise.
I'm not hearing Very soon.... just saying... Sounds more like another month or so....
Transaction Date Transaction
Type Market Value Shares Price Range Total Holdings
03/20/2014 Exercise of Stock Options Direct $592,436 639,248 0.75-0.95 6,037,350
11/16/2012 Purchase Direct $0 666,666 0.00-0.00 5,398,100
12/05/2011 Exercise of Stock Options Direct $75,000 100,000 0.75-0.75 4,731,440
12/01/2011 Exercise of Stock Options Direct $93,000 100,000 0.93-0.93 4,631,440
11/23/2011 Exercise of Stock Options Direct $93,000 100,000 0.93-0.93 4,531,440
10/19/2011 Exercise of Stock Options Direct $93,000 100,000 0.93-0.93 4,431,440
09/07/2011 Exercise of Stock Options Direct $93,000 100,000 0.93-0.93 4,331,440
07/29/2011 Exercise of Stock Options Direct $100,000 100,000 1.00-1.00 4,231,440
05/03/2011 Exercise of Stock Options Direct $100,000 100,000 1.00-1.00 4,131,440
04/20/2011 Exercise of Stock Options Direct $100,000 100,000 1.00-1.00 4,031,440
04/12/2011 Exercise of Stock Options Direct $150,000 150,000 1.00-1.00 3,931,440
02/07/2011 Exercise of Stock Options Direct $6,250 8,333 0.75-0.75 3,781,440
02/03/2011 Exercise of Stock Options Direct $93,750 125,000 0.75-0.75 3,773,100
12/29/2010 Exercise of Stock Options Direct $400,000 400,000 1.00-1.00 3,648,100
11/19/2010 Exercise of Stock Options Direct $100,000 100,000 1.00-1.00 3,248,100
09/07/2010 Exercise of Stock Options Direct $100,000 100,000 1.00-1.00 3,148,100
07/09/2010 Exercise of Stock Options Direct $82,500 75,000 1.10-1.10 3,048,100
04/28/2010 Exercise of Stock Options Direct $106,814 157,888 0.64-0.75 2,973,100
12/22/2009 Exercise of Stock Options Direct $93,634 98,334 0.94-1.02 2,815,220
08/26/2009 Exercise of Stock Options Direct $47,000 50,000 0.94-0.94 2,716,880
This development track, separate from the phase 3 study, using PV-10 in combination with checkpoint protein inhibitors could present a path forward for patients with significant disease burden not amenable to intralesional injection.